Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 62

1.

A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling.

Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, Febbo PG, Shak S, Kattan MW, Lee M, Carroll PR.

Eur Urol. 2014 May 16. pii: S0302-2838(14)00414-X. doi: 10.1016/j.eururo.2014.05.004. [Epub ahead of print]

PMID:
24836057
[PubMed - as supplied by publisher]
2.

Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy.

Van Allen EM, Foye A, Wagle N, Kim W, Carter SL, McKenna A, Simko JP, Garraway LA, Febbo PG.

Prostate Cancer Prostatic Dis. 2014 Mar;17(1):23-7. doi: 10.1038/pcan.2013.37. Epub 2013 Dec 24.

PMID:
24366412
[PubMed - in process]
3.

Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer--factors affecting diagnostic success.

Spritzer CE, Afonso PD, Vinson EN, Turnbull JD, Morris KK, Foye A, Madden JF, Roy Choudhury K, Febbo PG, George DJ.

Radiology. 2013 Dec;269(3):816-23. doi: 10.1148/radiol.13121782. Epub 2013 Oct 28.

PMID:
23925271
[PubMed - indexed for MEDLINE]
4.

Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways.

Klink JC, Tewari AK, Masko EM, Antonelli J, Febbo PG, Cohen P, Dewhirst MW, Pizzo SV, Freedland SJ.

Prostate. 2013 May;73(7):754-62. doi: 10.1002/pros.22619. Epub 2012 Nov 28.

PMID:
23192356
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Chromatin accessibility reveals insights into androgen receptor activation and transcriptional specificity.

Tewari AK, Yardimci GG, Shibata Y, Sheffield NC, Song L, Taylor BS, Georgiev SG, Coetzee GA, Ohler U, Furey TS, Crawford GE, Febbo PG.

Genome Biol. 2012 Oct 3;13(10):R88. doi: 10.1186/gb-2012-13-10-r88.

PMID:
23034120
[PubMed - in process]
Free PMC Article
6.

Predictive biomarkers in advance of a companion drug: ahead of their time?

Kelley RK, Atreya C, Venook AP, Febbo PG.

J Natl Compr Canc Netw. 2012 Mar;10(3):303-9.

PMID:
22393192
[PubMed - indexed for MEDLINE]
7.

Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer.

Kim MK, Osada T, Barry WT, Yang XY, Freedman JA, Tsamis KA, Datto M, Clary BM, Clay T, Morse MA, Febbo PG, Lyerly HK, Hsu DS.

Mol Cancer Ther. 2012 Jul;11(7):1500-9. doi: 10.1158/1535-7163.MCT-11-0937. Epub 2012 Feb 16.

PMID:
22351745
[PubMed - indexed for MEDLINE]
Free Article
8.

An animal model of MYC-driven medulloblastoma.

Pei Y, Moore CE, Wang J, Tewari AK, Eroshkin A, Cho YJ, Witt H, Korshunov A, Read TA, Sun JL, Schmitt EM, Miller CR, Buckley AF, McLendon RE, Westbrook TF, Northcott PA, Taylor MD, Pfister SM, Febbo PG, Wechsler-Reya RJ.

Cancer Cell. 2012 Feb 14;21(2):155-67. doi: 10.1016/j.ccr.2011.12.021.

PMID:
22340590
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

NCCN molecular testing white paper: effectiveness, efficiency, and reimbursement.

Engstrom PF, Bloom MG, Demetri GD, Febbo PG, Goeckeler W, Ladanyi M, Loy B, Murphy K, Nerenberg M, Papagni P, Robson M, Sweetman RW, Tunis S, Demartino J, Larsen JK; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Dec;9 Suppl 6:S1-16.

PMID:
22203777
[PubMed - indexed for MEDLINE]
10.

NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.

Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, Iafrate AJ, Kelley RK, Marcucci G, Ogino S, Pao W, Sgroi DC, Birkeland ML.

J Natl Compr Canc Netw. 2011 Nov;9 Suppl 5:S1-32; quiz S33.

PMID:
22138009
[PubMed - indexed for MEDLINE]
11.

Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center.

Stewart SB, BaƱez LL, Robertson CN, Freedland SJ, Polascik TJ, Xie D, Koontz BF, Vujaskovic Z, Lee WR, Armstrong AJ, Febbo PG, George DJ, Moul JW.

J Urol. 2012 Jan;187(1):103-8. doi: 10.1016/j.juro.2011.09.040. Epub 2011 Nov 16.

PMID:
22088334
[PubMed - indexed for MEDLINE]
12.

Immune signatures predict prognosis in localized cancer.

Hsu DS, Kim MK, Balakumaran BS, Acharya CR, Anders CK, Clay T, Lyerly HK, Drake CG, Morse MA, Febbo PG.

Cancer Invest. 2010 Aug;28(7):765-73. doi: 10.3109/07357900903095755.

PMID:
20569070
[PubMed - indexed for MEDLINE]
13.

A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.

Armstrong AJ, Netto GJ, Rudek MA, Halabi S, Wood DP, Creel PA, Mundy K, Davis SL, Wang T, Albadine R, Schultz L, Partin AW, Jimeno A, Fedor H, Febbo PG, George DJ, Gurganus R, De Marzo AM, Carducci MA.

Clin Cancer Res. 2010 Jun 1;16(11):3057-66. doi: 10.1158/1078-0432.CCR-10-0124. Epub 2010 May 25.

PMID:
20501622
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

MYC activity mitigates response to rapamycin in prostate cancer through 4EBP1-mediated inhibition of autophagy.

Balakumaran BS, Herbert JT, Febbo PG.

Autophagy. 2010 Feb;6(2):281-2. Epub 2010 Feb 10.

PMID:
20026909
[PubMed - indexed for MEDLINE]
Free Article
15.

Cancer gene profiling in prostate cancer.

Foye A, Febbo PG.

Methods Mol Biol. 2010;576:293-326. doi: 10.1007/978-1-59745-545-9_15.

PMID:
19882268
[PubMed - indexed for MEDLINE]
16.

MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy.

Balakumaran BS, Porrello A, Hsu DS, Glover W, Foye A, Leung JY, Sullivan BA, Hahn WC, Loda M, Febbo PG.

Cancer Res. 2009 Oct 1;69(19):7803-10. doi: 10.1158/0008-5472.CAN-09-0910. Epub 2009 Sep 22.

PMID:
19773438
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.

Armstrong AJ, Febbo PG.

Oncologist. 2009 Aug;14(8):816-27. doi: 10.1634/theoncologist.2009-0043. Epub 2009 Aug 14. Review.

PMID:
19684076
[PubMed - indexed for MEDLINE]
Free Article
18.

Genomic approaches to outcome prediction in prostate cancer.

Febbo PG.

Cancer. 2009 Jul 1;115(13 Suppl):3046-57. doi: 10.1002/cncr.24350. Review.

PMID:
19544546
[PubMed - indexed for MEDLINE]
Free Article
19.

Epigenetic events highlight the challenge of validating prognostic biomarkers during the clinical and biologic evolution of prostate cancer.

Febbo PG.

J Clin Oncol. 2009 Jul 1;27(19):3088-90. doi: 10.1200/JCO.2008.20.9783. Epub 2009 May 26. Review. No abstract available.

PMID:
19470924
[PubMed - indexed for MEDLINE]
Free Article
20.

The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model.

Mavropoulos JC, Buschemeyer WC 3rd, Tewari AK, Rokhfeld D, Pollak M, Zhao Y, Febbo PG, Cohen P, Hwang D, Devi G, Demark-Wahnefried W, Westman EC, Peterson BL, Pizzo SV, Freedland SJ.

Cancer Prev Res (Phila). 2009 Jun;2(6):557-65. doi: 10.1158/1940-6207.CAPR-08-0188. Epub 2009 May 26.

PMID:
19470786
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk